

# Cost prediction of antipsychotic medication of psychiatric disorder using artificial neural network model

Arash Mirabzadeh, Enayatollah Bakhshi<sup>1</sup>, Mohamad Reza Khodae<sup>2</sup>, Mohamad Reza Kooshesh<sup>3</sup>, Bibi Riahi Mahabadi<sup>4</sup>, Hossein Mirabzadeh<sup>5</sup>, Akbar Biglarian<sup>1</sup>

Department of Psychiatric, Social Determinants of Health Research Center, <sup>1</sup>Department of Biostatistics, <sup>2</sup>Department of Psychiatric, <sup>3</sup>Master of Sciences of Psychology, Pediatric Neurorehabilitation Research Center, University of Social Welfare and Rehabilitation Sciences (USWRS), Tehran, Iran, <sup>4</sup>Master of Sciences of Psychology, Family Clinic, Shahid Beheshti University of Medical Sciences and Health Services, <sup>5</sup>Master of Industrial Psychology, Tehran, Iran.

**Background:** Antipsychotic monotherapy or polypharmacy (concurrent use of two or more antipsychotics) are used for treating patients with psychiatric disorders (PDs). Usually, antipsychotic monotherapy has a lower cost than polypharmacy. This study aimed to predict the cost of antipsychotic medications (AM) of psychiatric patients in Iran. **Materials and Methods:** For this purpose, 790 patients with PDs who were discharged between June and September 2010 were selected from Razi Psychiatric Hospital, Tehran, Iran. For cost prediction of AM of PD, neural network (NN) and multiple linear regression (MLR) models were used. Analysis of data was performed with R 2.15.1 software. **Results:** Mean  $\pm$  standard deviation (SD) of the duration of hospitalization (days) in patients who were on monotherapy and polypharmacy was  $31.19 \pm 15.55$  and  $36.69 \pm 15.93$ , respectively ( $P < 0.001$ ). Mean and median costs of medication for monotherapy ( $n = 507$ ) were \$8.25 and \$6.23 and for polypharmacy ( $n = 192$ ) were \$13.30 and \$9.48, respectively ( $P = 0.001$ ). The important variables for cost prediction of AM were duration of hospitalization, type of treatment, and type of psychiatric ward in the MLR model, and duration of hospitalization, type of diagnosed disorder, type of treatment, age, Chlorpromazine dosage, and duration of disorder in the NN model. **Conclusion:** Our findings showed that the artificial NN (ANN) model can be used as a flexible model for cost prediction of AM.

**Key words:** Linear regression, neural networks, psychiatric disorders, treatment cost

**How to cite this article:** Mirabzadeh A, Bakhshi E, Khodae MR, Kooshesh MR, Mahabadi BR, Mirabzadeh H, *et al.* Cost prediction of antipsychotic medication of psychiatric disorder using artificial neural network model. *J Res Med Sci* 2013;18:782-5.

## INTRODUCTION

Over the past 40 years, antipsychotic monotherapy or polypharmacy medications have been used as treatment modalities for psychiatric disorders (PDs).<sup>[1-4]</sup> However, it seems that antipsychotic polypharmacy has increased for schizophrenia patients over time, especially when monotherapy fails to act as an effective mode of treatment.<sup>[4-6]</sup> According to the World Health Organization (WHO) estimates, schizophrenia affects approximately 24 million people worldwide.<sup>[7,8]</sup> This PD imposes great cost burden on the individual and society. The prevalence of antipsychotic polypharmacy has been reported to be between 13 and 70%.<sup>[4,9-12]</sup> Despite advantages or disadvantages of antipsychotic polypharmacy, it increases treatment costs at a time of increasing budget constraints.<sup>[4,12-17]</sup> In the United Kingdom, 20.0% of the total burden of disease was attributable to mental illness compared with 17.2% to cardiovascular diseases and 15.5% to cancer. The cost

of treatment of mental health problems in the United Kingdom increased approximately from £42 billion in 2003 to £110 billion per annum in 2010.<sup>[18,19]</sup> The cost of treatment of mental health problems in the United States was approximately \$193 billion per year.<sup>[20,21]</sup> In Iran there is no national registry for these patients. Therefore, the exact number of individuals with schizophrenia and the burden of cost are unknown, although in regional studies, the prevalence of the disease was estimated at 0.3-0.5% for the adult population.<sup>[22,23]</sup>

The analysis of PD data and its prediction was made by using statistical methods and, recently, artificial neural networks (ANNs).<sup>[24-28]</sup> ANNs are computer programs that model the capabilities of the human brain by simulating the structure and function of neurons in the brain. Usually, an ANN model has three layers that are called the input, middle, and output layers. The input and output layers contain the predictors and the outcomes, respectively. The hidden layer contains

**Address for correspondence:** Dr. Akbar Biglarian, Department of Biostatistics, University of Social Welfare and Rehabilitation Sciences (USWRS), Koodakyar Street, Daneshjoo Ave, Evin, Tehran, Iran. E-mail: abiglarian@uswr.ac.ir

**Received:** 15-01-2013; **Revised:** 01-05-2013; **Accepted:** 14-07-2013

unobservable nodes and applies a nonlinear transformation to the linear combination of the input layer. These models are flexible, and nonlinear methods allow better fit to the data by exploring and modeling the relationships between input and output variables; this leads to accurate prediction.<sup>[29,30]</sup>

However, cost prediction of antipsychotic medication (AM) of psychiatric patients was not done in these studies. In the present study, the ANN model was used to predict the cost of AM of PD as an alternative approach and then its accuracy was compared to a multiple linear regression (MLR) model.

## MATERIALS AND METHODS

In this study, we analyzed the data from 790 patients with PD who were discharged between June and September 2010, and were selected from Razi Psychiatric Hospital, Tehran, Iran. The Research Ethics Committee of University of social welfare and rehabilitation sciences (USWRS) approved the study (project number 92/801/1/10406). The natural logarithm of cost of AM (in US dollars) was considered as the outcome variable. The covariates for this outcome consisted of age (in years), gender (male/female), education (illiterate/primary/middle school/diploma and higher), duration of hospitalization (in days), duration of disorder (in years), type of psychiatric ward (educational/noneducational), type of treatment of psychiatric disorder (monotherapy/polypharmacy), chlorpromazine dosage, and type of diagnosed disorder.

To predict cost of AM by MLR, the stepwise selection method was used and *P* values less than 0.05 were considered significant. In the ANN strategy, initially, the data was divided into two subsets: Training/learning (60%) and testing/validation (40%) subsets. The model-building process was made on training dataset based on a three-layer multilayer perceptron (MLP) with eight variables in the input layer, 4 to 14 nodes in the middle layer, and one node in the output layer. In addition, a back propagation learning algorithm was used and activation function was considered as sigmoid and identity in middle and output layers, respectively. Afterward, the model was validated by testing dataset. Here, the mean squared error of prediction (MSPR) was used for comparing the prediction ability of the described models. Data were analyzed using the R 2.15.1 software.<sup>[31]</sup>

## RESULTS

Six hundred and twelve (77.5%) of the psychiatric patients were men and the rest were women; 33.4% of the diagnosed disorders were schizophrenia. In addition, 519 (65.7%) of the patients were on monotherapy [Table 1]. For 75% of

**Table 1: General characteristics of the patients with PDs**

| Variables                        | No  | %    |
|----------------------------------|-----|------|
| Gender                           |     |      |
| Male                             | 612 | 77.5 |
| Female                           | 178 | 22.5 |
| Educational status               |     |      |
| Illiterate                       | 65  | 8.2  |
| Primary                          | 435 | 55.1 |
| Middle school                    | 128 | 16.2 |
| Diploma                          | 112 | 14.2 |
| Other                            | 48  | 6.1  |
| Treatment                        |     |      |
| Monotherapy                      | 519 | 65.7 |
| Polypharmacy                     | 197 | 24.9 |
| Unknown                          | 74  | 9.4  |
| Type of ward                     |     |      |
| Educational                      | 390 | 49.4 |
| Noneducational                   | 392 | 49.6 |
| Unknown                          | 8   | 1.0  |
| Type of diagnosed disorder       |     |      |
| Schizophrenia                    | 264 | 33.4 |
| Bipolar I                        | 211 | 26.7 |
| Bipolar Schizoaffective disorder | 64  | 8.1  |
| Other disorders                  | 251 | 31.8 |

PD=Psychiatric disorder

the patients, the prescribed chlorpromazine equivalent dosage was 250 to 1000 mg. Median of chlorpromazine dosage in monotherapy and polypharmacy was 600 and 900 mg, respectively. Mean  $\pm$  standard deviation (SD) age for patients on monotherapy and polypharmacy was  $35.64 \pm 11.96$  and  $34.81 \pm 11.34$  (in years), respectively. In addition, median age of these patients was 34. Mean  $\pm$  SD of duration of hospitalization for patients on monotherapy and polypharmacy was  $31.19 \pm 15.55$  and  $36.69 \pm 15.93$  (in days), respectively. Mean and median costs of medication for monotherapy ( $n = 507$ ) were \$8.25 and \$6.23, and for polypharmacy ( $n = 192$ ) were \$13.30 and \$9.48, respectively. In addition, 67.0 and 79.2% of the patients were on monotherapy in educational and noneducational wards, respectively, and others on polypharmacy. Median costs of medication in the educational and noneducational wards were \$6.02 and \$7.89, respectively.

Based on importance analysis in the ANN strategy, duration of hospitalization, type of diagnosed disorder, type of treatment, age, chlorpromazine dosage, and duration of disorder were determined as ordered important factors for the cost prediction of the patients [Table 2].

For comparing the prediction ability of the models, we used MSPR for the testing subset. The results are presented in Table 3. The MSPR showed that the ANN prediction was better than MLR model (MSPR was 1.147 vs. 1.652 for first-order and 1.590 for second-order model).

**Table 2: ANN and MLR modeling results to determine the important factors for PD patients**

| ANN model                   |            | MLR model                   |         |
|-----------------------------|------------|-----------------------------|---------|
| Ordered* variables          | Importance | Ordered** variables         | P-value |
| Duration of hospitalization | 0.286      | Duration of hospitalization | 0.000   |
| Type of diagnosed disorder  | 0.139      | Type of treatment           | 0.003   |
| Type of treatment           | 0.124      | Type of ward                | 0.045   |
| Age                         | 0.110      | Type of diagnosed disorder  | 0.065   |
| Chlorpromazine dosage       | 0.102      | Chlorpromazine dosage       | 0.151   |
| Duration of disorder        | 0.100      | Duration of disorder        | 0.172   |
| Educational status          | 0.075      | Age                         | 0.253   |
| Gender                      | 0.038      | Educational status          | 0.321   |
| Type of ward                | 0.026      | Gender                      | 0.921   |

ANN=Artificial neural network; MLR=Multiple linear regression; PD=Psychiatric disorder, \*According to importance column; \*\*According to P-value column

**Table 3: Comparison of results for ANN model with MLR**

|                     | ANN   | MLR               |                    |
|---------------------|-------|-------------------|--------------------|
|                     |       | First-order model | Second-order model |
| Number of parameter | 119   | 9                 | 54                 |
| MSE                 | 0.498 | 0.613             | 0.654              |
| MSPR                | 1.147 | 1.652             | 1.590              |

ANN=Artificial neural network; MLR=Multiple linear regression

## DISCUSSION

During the past decade, prescriptions of antipsychotic polypharmacy medications have increased, especially for adult patients with PDs.<sup>[32]</sup> In addition, fees for the services are enormous, especially for individuals with severe PDs.<sup>[32,33]</sup> However, some studies reported predictors of hospitalization and the cost burden of schizophrenia.<sup>[13,16,17,24-28,34]</sup> Among these studies, the ANN model has been used to predict length of hospital stay for psychiatric diagnosis-related groups,<sup>[24]</sup> to determine the number of state psychiatric hospital beds,<sup>[25]</sup> to identify patients with schizophrenia,<sup>[26]</sup> and to identify metabolic syndrome in patients treated with second-generation antipsychotics.<sup>[27]</sup> These studies showed that the ANN model can be used as a powerful predictive tool.

The applications of NNs were reported in different medical fields such as cancer, clinical decision support, telemedicine, and self-care. It is mentioned that their accuracy in predictions depends on better integration with data, information, and clinical protocols.<sup>[35]</sup> As a result, in many applications, NNs have shown better prediction ability compared to traditional statistical methods.<sup>[36]</sup> In a review study, application of ANNs and statistical methods was compared. Of 96 studies, ANN performed better than regression models in 58% of the cases, and in 24% of the cases, ANN performed equal to statistical methods.<sup>[37]</sup> Generally in prediction or classification problems, ANN models are better than the usual statistical models. In this sense, with acceptable training process, an ANN will be able to predict new data correctly. In this study, we used

the ANN and MLR models for prediction of the cost of ATM. The results showed that the prediction of the ANN model was better than that of the MLR model. So, the ANN model can be used as a powerful and flexible model for the cost prediction of AM. Given that most of the cost of care for the mentally ill in the public or private sector is thrust on the patient's family, prediction of the cost of treatment is beneficial. In addition, PDs usually require frequent or prolonged hospitalization. Consequently, accurate prediction of the cost of treatment would be helpful for the patients and their families.

## ACKNOWLEDGMENT

The authors wish to express their gratitude to all colleagues at Razi Psychiatric Hospital and also to the Deputy of Research and Technology for financial support.

## REFERENCES

1. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, *et al.* Practice guideline for the treatment of patients with schizophrenia. Second edition. *Am J Psychiatry* 2004;161(Suppl 2):1-56.
2. Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. *J Clin Psychiatry* 2004;65:1377-88.
3. Millier A, Sarlon E, Azorin JM, Boyer L, Aballea S, Auquier P, *et al.* Relapse according to antipsychotic treatment in schizophrenic patients: A propensity-adjusted analysis. *BMC Psychiatry* 2011;11:24.
4. Ye W, Ascher-Svanum H, Tanji Y, Flynn JA, Takahashi M, Conley RR. Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: A health care database analysis. *Neuropsychiatr Dis Treat* 2012;8:259-66.
5. Ghaemi SN. "All the worse for the fishes": Conceptual and historical background of polypharmacy in psychiatry. In: Ghaemi SN, editor. *Polypharmacy in Psychiatry*. New York (NY): Marcel Dekker; 2002. p. 1-34.
6. Oepen G. Polypharmacy in schizophrenia. In: Ghaemi SN, editor. *Polypharmacy in Psychiatry*. New York (NY): Marcel Dekker; 2002. p. 101-32.
7. Piccinelli M, Gomez Homen F. Gender differences in the epidemiology of affective disorders and schizophrenia. *Division*

- of Mental Health and Prevention of substance abuse. Geneva: World Health Organization (WHO); 1997. Available from: [http://www.who.int/mental\\_health/media/en/54.pdf](http://www.who.int/mental_health/media/en/54.pdf), [Last accessed on 2010 Nov 12].
8. García-Ruiz AJ, Pérez-Costillas L, Montesinos AC, Alcalde J, Oyagüez I, Casado MA. Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses. *Health Econ Rev* 2012;2:8.
  9. Procyshyn RM, Kennedy NB, Tse G, Thompson B. Antipsychotic polypharmacy: A survey of discharge prescriptions from a tertiary care psychiatric institution. *Can J Psychiatry* 2001;46:334-39.
  10. Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N. Combination antipsychotic therapy in clinical practice. *Psychiatr Serv* 2003;54:55-9.
  11. Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. *J Clin Psychiatry* 2004;65:1377-88.
  12. Ye W, Ascher-Svanum H, Tanji Y, Flynn JA, Takahashi M, Conley RR. Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: A health care database analysis. *Neuropsychiatr Dis Treat*. 2012;8:259-266.
  13. Zhu B, Ascher-Svanum H, Faries DE, Correll CU, Kane JM. Cost of antipsychotic polypharmacy in the treatment of schizophrenia. *BMC Psychiatry* 2008;8:19.
  14. Peng X, Ascher-Svanum H, Faries DE, Stauffer VL, Kollack-Walker S, Kinon BJ, *et al.* Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy. *Clinicoecon Outcomes Res* 2011;3:79-87.
  15. Peng X, Ascher-Svanum H, Faries D, Conley RR, Schuh KJ. Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia. *Clinicoecon Outcomes Res* 2011;3:9-14.
  16. De Silva J, Hanwella R, de Silva VA. Direct and indirect cost of schizophrenia in outpatients treated in a tertiary care psychiatry unit. *Ceylon Med J* 2012;57:14-8.
  17. García-Ruiz AJ, Pérez-Costillas L, Montesinos AC, Alcalde J, Oyagüez I, Casado MA. Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses. *Health Econ Rev* 2012;2:8.
  18. Sainsbury Centre for Mental Health). The economic and social costs of mental illness. Policy Paper 3. London: Sainsbury Centre for Mental Health; 2003.
  19. McCrone P, Dhanasiri S, Patel A, Knapp M, Lawton-Smith S. Paying the price: The cost of mental health care in England to 2026. London: King's Fund; 2008.
  20. Insel TR. Assessing the economic costs of serious mental illness. *Am J Psychiatry* 2008;165:663-5.
  21. Mental health and Psychiatry news. Available from: <http://www.health.am/psy/more/american-adults-have-a-mood-or-anxiety-disorder/> [Last accessed on 2010 Nov 01].
  22. Mohammadi MR, Davidian H, Nourbala AA, Malek Afzali H, Naghavi HR, Pouretamad HR, *et al.* An epidemiological study of psychiatric disorders in Iran, 2001. *Hakim Med J* 2003;6:55-67.
  23. Noorbala AA, Bagheri Yazdi SA, Yasamy MT, Mohammad K. Mental health survey of adult population in Iran. *Br J Psychiatry* 2004;184:70-3.
  24. Lowell WE, Davis GE. Predicting length of stay for psychiatric diagnosis-related groups using neural networks. *J Am Med Inform Assoc* 1994;1:459-66.
  25. Davis GE, Lowell WE, Davis GL. Determining the number of state psychiatric hospital beds by measuring quality of care with artificial neural networks. *Am J Med Qual* 1998;13:13-24.
  26. Campana A, Duci A, Gambini O, Scarone S. An artificial neural network that uses eye-tracking performance to identify patients with schizophrenia. *Schizophr Bull* 1999;25:789-99.
  27. Lin CC, Bai YM, Chen JY, Hwang TJ, Chen TT, Chiu HW, *et al.* Easy and low-cost identification of metabolic syndrome in patients treated with second-generation antipsychotics: Artificial neural network and logistic regression models. *J Clin Psychiatry* 2010;71:225-34.
  28. Chisholm D, Saxena S. Cost effectiveness of strategies to combat neuropsychiatric conditions in sub-Saharan Africa and South East Asia: Mathematical modelling study. *BMJ* 2012;344:e609.
  29. Bishop CM. *Neural networks for pattern recognition*. New York: Oxford University Press; 1995.
  30. Ripley BD. *Pattern recognition and neural networks*. London: Cambridge University Press; 1996.
  31. The R Core team. The comprehensive R archive network (CRAN): An open source software. Available from: <http://www.cran.r-project.org/>. [Last accessed on 2012 Jul].
  32. Constantine RJ, Boaz T, Tandon R. Antipsychotic polypharmacy in the treatment of children and adolescents in the fee-for-service component of a large state Medicaid program. *Clin Ther* 2010;32:949-59.
  33. Constantine R, Tandon R. Changing trends in pediatric antipsychotic use in Florida's Medicaid program. *Psychiatr Serv* 2008;59:1162-8.
  34. Zeidler J, Slawik L, Fleischmann J, Greiner W. The costs of schizophrenia and predictors of hospitalisation from the statutory health insurance perspective. *Health Econ Rev* 2012;2:9.
  35. Lisboa PJ. A review of evidence of health benefit from artificial neural networks in medical intervention. *Neural Netw* 2002;15:11-39.
  36. Fallah N, Gu H, Kazem M, Seyyedsalehi SA, Nourijelyani K, Eshraghian MR. Nonlinear Poisson regression using neural networks: A simulation study. *Neural Comput Appl* 2009;18:939-43.
  37. Paliwal M, Kumar UA. Neural networks and statistical techniques: A review of applications. *Expert Sys Appl* 2009;36:2-17.

**Source of Support:** Deputy of researches and technology of university of social welfare and rehabilitation sciences (USWRS), **Conflict of Interest:** None declared.